You are currently viewing The MUSE(TM) Procedure for GERD Treatment Performed First Time in Israel at Shaare-Zedek Medical Center

Dec 27, 2017 –  Dr. Wengrower, Head, Therapeutic Endoscopy Unit, and his colleagues Dr. Paz and Dr. Livovsky at the Digestive Diseases Institute, Shaare-Zedek Medical Center, carried out the first MUSE (TM) procedure for GERD treatment in Israel last December. Dr. Wengrower reported that the patient who had undergone the procedure felt minimal discomfort during the procedure, and was released from the hospital after two days, with no complications.

The MUSE system is a single-use flexible transoral stapler that merges the latest advancement in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication, the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD). As the device requires no incisions, patients generally report greater comfort during the procedure and experience reduced hospital stays by up to 50% over invasive fundoplication procedures.

“With up to twelve and a half percent of the adult Israeli population experiencing GERD symptoms on a weekly basis1, I am excited to help bring the MUSE system to Israel to reduce the need for pharmaceuticals and invasive surgical procedures for the treatment of GERD,” said Dr. Wengrower. “The incision-less procedure reduces surgery time and hospital stays, offering an attractive alternative to current GERD treatments.”

Those who experience symptoms such as heartburn or regurgitation twice a week or more, may be at risk for persistent GERD.

Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. Medigus is the developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world – it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit or

For more information, see: NASDAQ Global Newswire